• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Vir Biotechnology Inc.

    11/5/25 9:47:13 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0002036234
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Vir Biotechnology, Inc.
    SEC File Number
    001-39083
    Address of Issuer
    1800 OWENS STREET
    SUITE 900
    SAN FRANCISCO
    CALIFORNIA
    94158
    Phone
    415-906-4324
    Name of Person for Whose Account the Securities are To Be Sold
    de Verneuil Vanina
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    238512306.6013891642611/05/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/01/2025Restricted Stock VestingIssuerCheckbox not checked238511/01/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Vanina A. Huard De Verneuil
    1800 Owens Street
    Suite 900
    San Francisco � CA � 94158
    Common11/03/202513658003.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/05/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/02/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Vanina Huard de Verneuil

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VIR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIR

    DatePrice TargetRatingAnalyst
    9/3/2025$12.00Outperform
    Evercore ISI
    8/27/2025$14.00Neutral → Buy
    BofA Securities
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    9/14/2022$40.00Outperform
    SVB Leerink
    More analyst ratings

    $VIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

    SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations ECLIPSE registrational program evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta fully underway, with topline data expected in the first quarter of 2027 Data presented at AASLD The Liver Meeting® and simultaneously published in the New England Journal of Medicine Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Week 48 endpoint analysis from t

    11/9/25 6:07:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

    Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer

    11/7/25 9:00:00 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    - ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the first quarter of 2027 - Comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, planned for the first quarter of 2026 - First patient dosed in Phase 1 study of VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) in first-line metastatic castration-resistant prostate cancer - Strong financial position and runway into mid-2027 with $810.7 million in cash and investments as of September 30, 2025 - Conference call scheduled for Nove

    11/5/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel, Corp Sec De Verneuil Vanina sold $12,307 worth of Common Stock (2,385 units at $5.16), decreasing direct ownership by 3% to 78,210 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    11/7/25 3:27:52 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP and General Counsel De Verneuil Vanina sold $8,003 worth of Common Stock (1,365 units at $5.86), decreasing direct ownership by 2% to 80,595 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    11/4/25 7:40:39 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sato Vicki L sold $124,047 worth of shares (22,000 units at $5.64), decreasing direct ownership by 2% to 1,210,391 units (SEC Form 4)

    4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

    11/4/25 11:58:05 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    SEC Filings

    View All

    SEC Form 10-Q filed by Vir Biotechnology Inc.

    10-Q - Vir Biotechnology, Inc. (0001706431) (Filer)

    11/5/25 5:15:30 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

    11/5/25 4:12:13 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Vir Biotechnology Inc.

    144 - Vir Biotechnology, Inc. (0001706431) (Subject)

    11/5/25 9:47:13 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Vir Biotechnology with a new price target

    Evercore ISI initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $12.00

    9/3/25 8:41:05 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology upgraded by BofA Securities with a new price target

    BofA Securities upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $14.00

    8/27/25 8:18:54 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology downgraded by JP Morgan with a new price target

    JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously

    1/29/24 7:27:38 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vir Biotechnology Inc.

    SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    10/18/24 12:29:43 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

    SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    2/13/24 5:17:30 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

    SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

    2/13/24 5:00:42 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Financials

    Live finance-specific insights

    View All

    Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    - ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the first quarter of 2027 - Comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, planned for the first quarter of 2026 - First patient dosed in Phase 1 study of VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) in first-line metastatic castration-resistant prostate cancer - Strong financial position and runway into mid-2027 with $810.7 million in cash and investments as of September 30, 2025 - Conference call scheduled for Nove

    11/5/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. The webcast may be accessed on the Events & Presentations page of the Vir Biotechnology website. Participants must register in advance to receive a unique webcast access link. An archived replay wil

    10/22/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    – ECLIPSE registrational program in chronic hepatitis delta fully underway – First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical pipeline with three ongoing Phase 1 studies – Strong financial position and runway into mid-2027 with approximately $892.1 million in cash and investments as of June 30, 2025 – Conference call scheduled for August 6, 2025 at 1:30 p.m. PT / 4:30 p.m. ET Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. "We achieved several important milestones across our pipeline, reflecting our

    8/6/25 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIR
    Leadership Updates

    Live Leadership Updates

    View All

    Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

    – ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027 – ECLIPSE registrational program on target, with ECLIPSE 2 and 3 enrolling well and in line with the Company's expectations – Swift recruitment underscores high unmet medical need for effective and convenient chronic hepatitis delta treatment Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE 1 is one of three t

    11/3/25 8:00:00 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

    – Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation

    9/10/24 8:05:00 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

    4/1/24 8:00:00 AM ET
    $LCTX
    $SYBX
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations